For the first timehttps://innovationtoronto.com/wp-content/uploads/2019/10/213780_webwe4.jpg, scientists have identified a simple way that can effectively transport medication into the brain – which could lead to improved treatments for neurological and neurodegenerative diseases.
In a study published today in Nature Communications, scientists from Newcastle University, UK, have led an international team in a major breakthrough in unlocking the secrets of how medications can infiltrate the brain.
Blood capillaries in the brain are not permeable to many drugs and the majority are excluded from the brain by a protective barrier, called the blood-brain-barrier (BBB), and current treatment options are risky.
Some viruses, however, have found ways to bypass the BBB and enter the brain. To treat certain neurological and neurodegenerative diseases, medication has to use modified viruses to bypass this barrier and deliver drugs to the area.
The team has now engineered small particles, similar to the size of viruses, from a peptide that can behave like a carrier to the brain and can be packed with drugs for intravenous injection.
Professor Moein Moghimi, who led the research, said: “Crossing the blood-brain-barrier has hindered the industry from effectively addressing central nervous system diseases, including brain tumours, and many neurological diseases like Parkinson’s, Alzheimer’s and Huntington’s.
“This breakthrough – based on more than 10 years of research – has significant implications for crossing BBB and other biological barriers that have created challenges for drug delivery.
“Our breakthrough allows for minimally invasive combination delivery through an intravenous injection of various drugs, peptides and nucleic acid therapeutics to the brain.”
At present, treatment of neurological disorders involves difficulties in ‘packaging’ viruses safely and medication is usually administered by injection into the cerebrospinal fluid, which is not without risks.
The new technological breakthrough in delivering genetic materials to cells in the brain has used a peptide component from a virus that targets the brain (a bacteriophage fd). The peptide was synthesised and modified slightly, and when water was added it spontaneously formed a ‘small, hairy particle’.
Scientists found that when the developed particle was injected into a mouse model, the system targeted the brain, crossing the blood-brain-barrier, reaching neurons and microglia cells in the brain.
Professor Moghimi added: “We are very excited by our research – our delivery system is versatile and amenable to modifications, so, in principle, we can hopefully address shortfalls in drug delivery to the brain through intravenous injection.
“We have a long way to go, but we hope that our technology platform may open up many opportunities to address neurodegenerative diseases with modern therapeutics and genetic drugs.”
Through the mouse model, scientists found their technique was safe. Further research will test the technology in animal disease models in preparation for clinical trials.
Gary Leo, SMDG’s SVP of Corporate Development and former national president and CEO of the ALS Association, USA, said: “Bearing in mind the fact that neurological disorders are growing in incidence faster than any other disease class worldwide, governments will face a huge burden and increasing demands for treatment and support services.
“New knowledge is required to develop effective treatment strategies, and the new technology reported in Nature Communications is a promising achievement to fulfil these goals.”
The Latest on: Blood-brain-barrier
via Google News
The Latest on: Blood-brain-barrier
- Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 ...on May 1, 2021 at 6:02 am
Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease BIIB122/DNL151 ...
- 3rd Annual Blood-Brain Barrier Summit | June 28-30, 2021on April 29, 2021 at 2:07 am
The 3 rd Annual Blood-Brain Barrier Summit is dedicated to helping drug developers enhance drug delivery across the Blood-Brain Barrier (BBB) to enable effective treatments for neurodegenerative ...
- Leaky Blood-Brain Barrier Linked to Schizophreniaon April 27, 2021 at 1:37 pm
Researchers from the University of Pennsylvania have found that people with schizophrenia may have a more permeable blood-brain barrier than people without the condition. A growing body of evidence is ...
- Blood-Brain Barrier (BBB) Market Size Worth USD 7.40 Billion in 2028, Market Trend – Advancements in healthcare infrastructureon April 26, 2021 at 3:56 pm
The global blood-brain barrier (BBB) market size is expected to reach USD 7.40 Billion in 2028 at a steady CAGR ...
- 'Leaky' blood-brain barrier may contribute to schizophreniaon April 24, 2021 at 5:01 pm
Share on Pinterest New research has pointed to a ‘leaky’ blood-brain barrier as a potential cause of schizophrenia. Jane Khomi/Getty Images The blood-brain barrier shields the central nervous ...
- Our Immune System Links the Blood-Brain Barrier to Schizophreniaon April 21, 2021 at 2:45 am
Researchers have shown that in people with schizophrenia and other mental disorders, the blood-brain barrier is more permissive, allowing the immune system to cause inflammation in the brain.
- The immune link between a leaky blood-brain barrier and schizophreniaon April 21, 2021 at 12:41 am
Like a stern bodyguard for the central nervous sytem, the blood-brain barrier keeps out anything that could lead to disease and dangerous inflammation—at least when all is functioning normally.
- Blood-brain barrier and its effect on the immune system play a role in schizophreniaon April 20, 2021 at 9:51 pm
Like a stern bodyguard for the central nervous sytem, the blood-brain barrier keeps out anything that could lead to disease and dangerous inflammation--at least when all is functioning normally.
- A leaky blood-brain barrier and schizophrenia risk (image)on April 20, 2021 at 11:31 am
A genetic condition known as 22q.11.2 deletion syndrome is associated with an increased risk of schizophrenia. A Penn Vet-led team found that a leaky blood-brain barrier, allowing inappropriate immune ...
via Bing News